公开(公告)号：US20240316099A1

公开(公告)日：2024-09-26

申请号：US18245281

申请日：2021-09-27

Applicant: Baylor College of Medicine

Inventor： Robin Parihar ,  Stephanie Fetzko ,  Tim Sauer

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K16/30 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/46447 ,  A61K39/464471 ,  C07K14/70503 ,  C07K16/3084 ,  C07K16/3092 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/21 ,  C07K2317/622 ,  C07K2319/03

Abstract: Disclosed herein are methods and compositions for cell-based immunotherapies that simultaneously target the tumor microenvironment (TME) via NKG2D ligands and tumor cells via tumor-associated antigens, specifically using immune effector cells as the platform due to their reduced toxicity against normal tissue. In some embodiments, immune effector cells co-express an NKG2D cytotoxic CAR and a CAR directed against a tumor-associated antigen that provides costimulatory signals to the immune effector cell, thus killing only in the presence of both antigens specifically within the TME. In contrast, within normal tissue that might express the tumor-associated antigen, but where self-HLA is also expressed, the costimulatory signal by itself is insufficient for immune effector cell activation, thereby preventing off-tumor toxicity.

公开(公告)号：US20240309110A1

公开(公告)日：2024-09-19

申请号：US18526205

申请日：2023-12-01

Applicant: DANMARKS TEKNISKE UNIVERSITET ,  UNIVERSIDAD DE ZARAGOZA ,  Fundación Agencia Aragonesa para la Investigación y el Desarrollo (ARAID)

Inventor： Ola Blixt ,  Ramón Hurtado Guerrero ,  Spyridon Gatos

IPC: C07K16/30 ,  A61K49/00 ,  C07K16/28 ,  C12N15/10

CPC classification number: C07K16/3092 ,  A61K49/0002 ,  C07K16/2896 ,  C12N15/1037 ,  A61K39/00 ,  C07K2317/24 ,  C07K2317/622

Abstract: The invention provides specific Tn- and/or STn antibody libraries and methods for identifying specific antibodies, which target Tn- and/or STn-glycosylation sites of any glycoprotein of choice, especially glycoproteins of cancer cell targets. The invention further provides antibodies identified by the new concept proposed herein, which have combined specificity towards both the sugar epitope as well as the peptide epitope of the glycoprotein.

公开(公告)号：US12091460B2

公开(公告)日：2024-09-17

申请号：US16906634

申请日：2020-06-19

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Jessica R. Kirshner ,  Alison Crawford ,  Danica Chiu

IPC: C07K16/46 ,  A61B6/00 ,  A61B6/03 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2809 ,  A61B6/037 ,  A61B6/481 ,  A61K51/1042 ,  C07K16/2878 ,  C07K16/3092 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/75

Abstract: Provided herein are method of treating cancer using bispecific antigen-binding molecules that bind to Mucin 16 (MUC16) and CD3. According to certain embodiments, the antibodies useful herein bind human MUC16 with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human MUC16 are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of tumors expressing MUC16, for example, ovarian tumors. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.

公开(公告)号：US12065503B2

公开(公告)日：2024-08-20

申请号：US17283988

申请日：2019-10-09

Applicant: ASTELLAS PHARMA INC.

Inventor： Jumpei Suemitsu ,  Megumi Ikeda ,  Moe Kohno

IPC: C07K16/30 ,  A61K47/10 ,  A61K47/26 ,  A61K51/04 ,  A61K51/10

CPC classification number: C07K16/3007 ,  A61K47/10 ,  A61K47/26 ,  A61K51/0446 ,  A61K51/1051 ,  A61K51/1093 ,  C07K16/3092 ,  C07K2317/55 ,  C07K2317/71

Abstract: Provided is a stable pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, and the like. In the pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or trishydroxymethyl aminomethane is added as a buffering agent, sucrose or glycerin is added as a stabilizer, a nonionic surfactant is added, and the pH is adjusted to 6.5 to 7.5. This enables suppression of generation of multimers and insoluble subvisible particles during preservation of the labeling moiety-anti-human antibody Fab fragment conjugate.

公开(公告)号：US12060434B2

公开(公告)日：2024-08-13

申请号：US17164696

申请日：2021-02-01

Applicant: Gensun Biopharma Inc.

Inventor： Margaret Karow ,  Richard Yau ,  Jackie Sheng

IPC: C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K16/3092 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2319/33

Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.

公开(公告)号：US20240180892A1

公开(公告)日：2024-06-06

申请号：US18473026

申请日：2023-09-22

Applicant: Immunomedics, Inc.

Inventor： Serengulam V. Govindan ,  David M. Goldenberg

IPC: A61K31/4745 ,  A61K31/00 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/502 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/675 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC classification number: A61K31/4745 ,  A61K31/00 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/502 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/675 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6853 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3092 ,  C07K16/32 ,  A61K2039/505 ,  C07K2317/92

Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, most preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer.

公开(公告)号：US11976133B2

公开(公告)日：2024-05-07

申请号：US17164699

申请日：2021-02-01

Applicant: Gensun Biopharma Inc.

Inventor： Margaret Karow ,  Richard Yau ,  Jackie Sheng

IPC: C07K16/30 ,  A61K39/00 ,  A61K45/06 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/3092 ,  A61K45/06 ,  C07K16/2809 ,  C07K16/2878 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75

Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.

公开(公告)号：US11933786B2

公开(公告)日：2024-03-19

申请号：US17097817

申请日：2020-11-13

Applicant: STCUBE, INC. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS

Inventor： Stephen S. Yoo ,  Ezra M. Chung ,  Yong-Soo Kim ,  Mien-Chie Hung ,  Chia-Wei Li ,  Seung-Oe Lim

IPC: C07H21/04 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: G01N33/57492 ,  C07K16/2827 ,  C07K16/3092 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532 ,  G01N2440/38

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

公开(公告)号：US11872289B2

公开(公告)日：2024-01-16

申请号：US17878611

申请日：2022-08-01

Applicant: DAIICHI SANKYO CO., LTD.

Inventor： Johanna Gellert ,  Anke Flechner ,  Doreen Weigelt ,  Antje Danielczyk ,  Akiko Nagase

IPC: A61K47/68 ,  A61K47/65 ,  A61K47/54 ,  A61P35/00 ,  A61K31/4745 ,  C07K16/30 ,  A61P35/02 ,  A61K39/395 ,  A61K39/00

CPC classification number: A61K47/6851 ,  A61K31/4745 ,  A61K39/39558 ,  A61K47/545 ,  A61K47/65 ,  A61K47/6803 ,  A61P35/00 ,  A61P35/02 ,  C07K16/3092 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.

公开(公告)号：US20240000933A1

公开(公告)日：2024-01-04

申请号：US18327255

申请日：2023-06-01

Applicant: Boehringer Ingelheim International GmbH

Inventor： Godfrey Jonah Anderson Rainey ,  Wolfgang Walter Scholz ,  Ritsuko Sawada

IPC: A61K39/395 ,  C07K16/44 ,  C07K16/30 ,  A61K47/68 ,  A61K47/64 ,  A61P35/00 ,  A61K51/10

CPC classification number: A61K39/39558 ,  C07K16/44 ,  C07K16/3092 ,  A61K47/6803 ,  A61K47/6415 ,  A61P35/00 ,  A61K51/1072 ,  C07K16/3015 ,  C07K2317/92 ,  C07K2317/565 ,  C07K2317/21 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/34

Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Tn antigen or sTn antigen. The compositions disclosed herein include isolated antibody or functional fragments thereof that binds to Tn antigen or sTn antigen and polynucleotides encoding the heavy chain and/or a light chain variable domains of such antibody or functional fragment. The invention also provides methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a localizing agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.